Avanos Medical, Inc. (AVNS)
NYSE: AVNS · Real-Time Price · USD
10.75
-0.04 (-0.37%)
Aug 13, 2025, 4:00 PM - Market closed
Avanos Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 692.5 | 687.8 | 673.3 | 684.1 | 587 | 714.8 | Upgrade
|
| Revenue Growth (YoY) | 1.48% | 2.15% | -1.58% | 16.54% | -17.88% | 2.47% | Upgrade
|
| Cost of Revenue | 319.7 | 306.5 | 293.6 | 289.9 | 287.8 | 343.9 | Upgrade
|
| Gross Profit | 372.8 | 381.3 | 379.7 | 394.2 | 299.2 | 370.9 | Upgrade
|
| Selling, General & Admin | 315.8 | 321.1 | 321.4 | 326.5 | 257.2 | 327.2 | Upgrade
|
| Research & Development | 10.3 | 12.4 | 12.6 | 29.2 | 30.6 | 34.9 | Upgrade
|
| Other Operating Expenses | 0.8 | 3 | 3.3 | 3 | 7.3 | 4.4 | Upgrade
|
| Operating Expenses | 326.9 | 336.5 | 337.3 | 358.7 | 295.1 | 366.5 | Upgrade
|
| Operating Income | 45.9 | 44.8 | 42.4 | 35.5 | 4.1 | 4.4 | Upgrade
|
| Interest Expense | -10.1 | -12.2 | -15 | -10 | -3.3 | -15.6 | Upgrade
|
| Interest & Investment Income | 3.6 | 5.1 | 2.9 | 1.2 | 0.2 | 1.2 | Upgrade
|
| EBT Excluding Unusual Items | 39.4 | 37.7 | 30.3 | 26.7 | 1 | -10 | Upgrade
|
| Merger & Restructuring Charges | -8.1 | -8.1 | -28.2 | - | -28.1 | -25.4 | Upgrade
|
| Impairment of Goodwill | -413.5 | -336.5 | - | - | - | - | Upgrade
|
| Asset Writedown | -100.2 | -100.2 | - | - | - | - | Upgrade
|
| Legal Settlements | 1.4 | - | -10 | - | -15 | -27.5 | Upgrade
|
| Other Unusual Items | 3.8 | 3.8 | - | - | - | - | Upgrade
|
| Pretax Income | -477.2 | -403.3 | -7.9 | 26.7 | -42.1 | -62.9 | Upgrade
|
| Income Tax Expense | -15.9 | -17 | 2 | 5.2 | -11.2 | -33.9 | Upgrade
|
| Earnings From Continuing Operations | -461.3 | -386.3 | -9.9 | 21.5 | -30.9 | -29 | Upgrade
|
| Earnings From Discontinued Operations | -1.9 | -5.8 | -51.9 | 29 | 37.2 | - | Upgrade
|
| Net Income | -463.2 | -392.1 | -61.8 | 50.5 | 6.3 | -29 | Upgrade
|
| Net Income to Common | -463.2 | -392.1 | -61.8 | 50.5 | 6.3 | -29 | Upgrade
|
| Net Income Growth | - | - | - | 701.59% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 46 | 46 | 47 | 47 | 48 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 46 | 47 | 47 | 49 | 48 | Upgrade
|
| Shares Change (YoY) | -1.07% | -1.29% | -1.48% | -2.67% | 1.67% | 0.42% | Upgrade
|
| EPS (Basic) | -10.06 | -8.52 | -1.33 | 1.08 | 0.13 | -0.61 | Upgrade
|
| EPS (Diluted) | -10.06 | -8.53 | -1.33 | 1.08 | 0.13 | -0.61 | Upgrade
|
| EPS Growth | - | - | - | 722.10% | - | - | Upgrade
|
| Free Cash Flow | 87.9 | 82.9 | 14.6 | 71.6 | 66.3 | -22.7 | Upgrade
|
| Free Cash Flow Per Share | 1.91 | 1.80 | 0.31 | 1.51 | 1.36 | -0.47 | Upgrade
|
| Gross Margin | 53.83% | 55.44% | 56.39% | 57.62% | 50.97% | 51.89% | Upgrade
|
| Operating Margin | 6.63% | 6.51% | 6.30% | 5.19% | 0.70% | 0.62% | Upgrade
|
| Profit Margin | -66.89% | -57.01% | -9.18% | 7.38% | 1.07% | -4.06% | Upgrade
|
| Free Cash Flow Margin | 12.69% | 12.05% | 2.17% | 10.47% | 11.29% | -3.18% | Upgrade
|
| EBITDA | 88.3 | 90.3 | 85.9 | 76.7 | 42.4 | 47.3 | Upgrade
|
| EBITDA Margin | 12.75% | 13.13% | 12.76% | 11.21% | 7.22% | 6.62% | Upgrade
|
| D&A For EBITDA | 42.4 | 45.5 | 43.5 | 41.2 | 38.3 | 42.9 | Upgrade
|
| EBIT | 45.9 | 44.8 | 42.4 | 35.5 | 4.1 | 4.4 | Upgrade
|
| EBIT Margin | 6.63% | 6.51% | 6.30% | 5.19% | 0.70% | 0.62% | Upgrade
|
| Effective Tax Rate | - | - | - | 19.48% | - | - | Upgrade
|
Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.